Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023
Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

In the competitive realm of healthcare and personal care, Hims & Hers Health (HIMS) faced a challenging month, witnessing a significant downturn of -12.69% and closing at $9.77 per share. This blog post aims to unravel the story behind Hims & Hers Health's notable setback, shedding light on the broader trends within the Household/Personal Care Industry. Join us as we dive into the analysis, examining the factors that contributed to the company's descent and exploring the market landscape that influenced its performance.

Understanding the Household/Personal Care Industry: To gain insights into Hims & Hers Health's performance, it is essential to understand the dynamics of the Household/Personal Care Industry. Our analysis of 95 stocks in this sector reveals that 47.37% exhibited an Uptrend, while 52.63% experienced a Downtrend. This industry overview sets the stage for comprehending the specific challenges and opportunities faced by Hims & Hers Health.

Factors Impacting Hims & Hers Health's Descent: Multiple factors may have influenced Hims & Hers Health's -12.69% monthly decline. Market conditions, competitive pressures, regulatory changes, or internal operational factors could have played a role in the company's setback. By examining these factors in detail, we can gain valuable insights into the circumstances that impacted Hims & Hers Health's performance.

Navigating the Landscape of Household/Personal Care: As investors evaluate the impact of Hims & Hers Health's descent, it becomes crucial to navigate the Household/Personal Care Industry with a discerning eye. Understanding the current market outlook, identifying potential opportunities, and assessing the risks associated with the sector are vital considerations for informed decision-making. This blog post provides valuable insights and strategies to help investors navigate the ever-evolving landscape of the Household/Personal Care Industry amidst Hims & Hers Health's downturn.

Hims & Hers Health's -12.69% monthly descent serves as a reminder of the volatility and challenges inherent in the Household/Personal Care Industry. By analyzing the broader market trends and uncovering the factors that influenced Hims & Hers Health's performance, investors can gain a comprehensive understanding of the landscape. In an industry that continues to evolve rapidly, staying informed, adapting to market conditions, and identifying potential opportunities while managing risks are crucial for investors seeking success in the Household/Personal Care sector.

Related Ticker: HIMS

HIMS in downward trend: price may decline as a result of having broken its higher Bollinger Band on June 15, 2026

HIMS broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 52 similar instances where the stock broke above the upper band. In of the 52 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HIMS moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.825) is normal, around the industry mean (46.452). P/E Ratio (57.137) is within average values for comparable stocks, (99.681). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.697). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (3.681) is also within normal values, averaging (114.852).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.05B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 17%. TLPH experienced the highest price growth at 27%, while BTAI experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
HIMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
658
Web
https://www.forhims.com
Interact to see
Advertisement
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
An AI-driven comparison of Netflix (NFLX) and Disney (DIS) points to Netflix as the more attractive investment heading into 2026. The analysis emphasizes Netflix’s focused, pure-play streaming model and its continued investment in original content, which support strong subscriber engagement as viewing habits shift further toward digital platforms.
An AI-driven comparison of Coca-Cola (KO) and PepsiCo (PEP) points to PepsiCo as the more compelling investment for 2026. The analysis emphasizes PepsiCo’s diversified business model, which combines beverages with a broad snack portfolio and provides greater resilience as consumer preferences evolve.
An AI-driven comparison of Philip Morris (PM) and British American Tobacco (BTI) points to Philip Morris as the more attractive investment for 2026. The analysis highlights PM’s accelerated transition toward smoke-free products, which positions the company for sustainable growth as global regulations continue to pressure traditional combustible tobacco.
SoundThinking, Inc. (SSTI), a developer of precision-policing and security technologies, has faced a difficult trading environment in recent weeks. With shares trading in the single digits, the stock reflects broader investor hesitation toward small-cap tech amid ongoing economic uncertainty. The company’s market capitalization stands near $100 million, and its valuation metrics suggest skepticism around its growth outlook.
Lionheart Holdings (CUB) has traded quietly in recent sessions, reflecting the typical behavior of a SPAC still in its pre-merger search phase. Shares have hovered close to the company’s IPO price, supported by low volatility and thin trading volumes. This pattern mirrors broader trends across the SPAC market, where investor engagement often remains subdued until a definitive acquisition agreement is announced.
Astronics Corporation has delivered solid share price performance in recent sessions, benefiting from renewed enthusiasm for aerospace and defense equities. The stock has demonstrated resilience despite broader market volatility, drawing consistent investor interest due to its exposure to mission-critical avionics, power systems, and test equipment.
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
General Dynamics shares have remained resilient in recent sessions, continuing an upward trend despite broader market volatility. Heightened attention on global defense spending has reinforced confidence in the company’s extensive backlog and well-balanced exposure across aerospace, marine systems, combat platforms, and mission-critical technologies.
Innovative Aerosystems (ISSC) has emerged as a standout performer within the aerospace and avionics space, with its stock reflecting optimism around rising demand for advanced cockpit and navigation systems. Recent trading has seen shares hold near the upper end of their range, supported by strong fundamentals and a diversified customer base spanning business aviation, commercial airlines, and military platforms.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.